New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...

AI’s hidden recession: How fewer jobs and cultural backlash create a governance crisis

AI will redefine how humans create value. Whether it also redefines who is allowed to create value will depend on the choices ...
The Sunday Guardian Live on MSNOpinion

Adaptive military engagement isn't ideological capture

A recent opinion piece has raised alarms about an alleged "ideological fusion" within India's armed forces, accusing them of ...